New hope for fertility: drug may reverse early menopause in autoimmune patients
NCT ID NCT07509840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an immunomodulatory drug (rituximab) can improve or normalize ovarian function in women aged 18-38 with autoimmune premature ovarian insufficiency (POI). Participants receive either rituximab or a placebo, and those who respond may undergo IVF. The goal is to restore fertility, but ongoing management may still be needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE PREMATUR OVARIAN INSUFFIENCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Obstetrics and Gynecology, Karolinska University Hospital
RECRUITINGStockholm, 171 76, Sweden
-
Karolinska University Hospital
RECRUITINGStockholm, 17176, Sweden